January 2020 Test Bulletin
January 29, 2020
Alverno Laboratories introduces significant updates in February 2020, including the consolidation of Drug of Abuse screening panels, resuming Lupus Anticoagulant Reflexive Panel testing, and offering an additional Anti-Phospholipid Syndrome Panel. Moreover, the Pain Management Panel testing transitions in-house, enhancing turnaround time and comprehensiveness. The Drug Screen Panel Updates feature consolidated panels with or without confirmation, with propoxyphene available as an individual screening test if needed. Additionally, the Lupus Anticoagulant and Anti-Phospholipid Syndrome Panels emphasize adherence to CLSI guidelines, incorporating prescreening tests and mixing studies. Lastly, the Pain Management Panel Update outlines comprehensive analytes and cutoffs, with improved specimen validity evaluation and a revised report template for enhanced usability.